Diabetic Cardiomyopathy Uncovered: Transcriptomics, NLRP3, and Carvedilol Mechanisms
Journal of Diabetes Research · 2024
DOI: 10.1155/2024/9378405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, 2024. Verfasst von Alimujiang Abudoureyimu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First People's Hospital of Kashi Prefecture, Kashi, China. Hauptthemen laut MEDLINE: Carvedilol, NLR Family, Pyrin Domain-Containing 3 Protein, Diabetic Cardiomyopathies, Myocytes, Cardiac. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study investigates the impact of a high‐sugar environment on H9C2 cardiomyocytes and explores the protective effects of carvedilol in the context of diabetic cardiomyopathy (Dia‐CM). Transcriptomic analysis identified 21,655 differentially expressed genes associated with Dia‐CM, demonstrating significant separation among samples.
Methods
H9C2 cardiomyocytes were cultured in a high‐sugar environment to simulate Dia‐CM conditions. Cell viability, cytokine levels, and protein expression were assessed using CCK‐8 assays, ELISA, and Western blot techniques. Intervention experiments with NLRP3, caspase‐1, and ROS inhibitors were conducted to evaluate their protective effects. The therapeutic potential of carvedilol was assessed by examining its impact on cell viability, cytokine levels, and key biomarkers. An in‐depth analysis of carvedilol’s regulatory effects on ROS and key proteins in H9C2 cells was also conducted.
Results
In vitro, a high‐sugar environment significantly reduced H9C2 cell survival, increased ROS levels, activated inflammatory responses, and upregulated NLRP3, caspase‐1, and GSDMD‐N proteins. Inhibitors of NLRP3, caspase‐1, and ROS ameliorated these effects. Carvedilol treatment improved cell activity, reduced inflammatory cytokine levels, suppressed ROS production, and downregulated NLRP3, pro‐caspase‐1, GSDMD‐N, and p‐NF‐ κ B proteins. Moderate‐dose carvedilol exhibited optimal intervention effects.
Conclusions
A high‐sugar environment induces cardiomyocyte damage through ROS production and NLRP3 inflammasome activation. Inhibitors of NLRP3, caspase‐1, and ROS provide effective protection. Carvedilol significantly mitigates the detrimental effects of a high‐sugar environment on H9C2 cardiomyocytes, potentially through inhibiting the NLRP3‐ASC inflammasome and caspase‐1/GSDMD‐dependent signaling pathway‐mediated pyroptosis. These findings offer insights into Dia‐CM mechanisms and highlight carvedilol as a promising therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First People's Hospital of Kashi Prefecture, Kashi, China.
ORCID-Profile: Alimujiang Abudoureyimu, Alimu Aihaiti, Nuliman Abudoujilili, Mayila Tuergong, Guzainuer Adili, Maihebubaimu Maimaiti, Dilinuer Mohetaer, Yimamumaimaiti Maiamaitishawuti
Zitieren
APA
Abudoureyimu, A., Aihaiti, A., Abudoujilili, N., Tuergong, M., Adili, G., Maimaiti, M., Mohetaer, D., & Maiamaitishawuti, Y. (2024). Diabetic Cardiomyopathy Uncovered: Transcriptomics, NLRP3, and Carvedilol Mechanisms. Journal of Diabetes Research. https://doi.org/10.1155/2024/9378405
Vancouver
Abudoureyimu A, Aihaiti A, Abudoujilili N, Tuergong M, Adili G, Maimaiti M, et al. Diabetic Cardiomyopathy Uncovered: Transcriptomics, NLRP3, and Carvedilol Mechanisms. Journal of Diabetes Research. 2024. doi:10.1155/2024/9378405
BibTeX
@article{Abudoureyimu2024,
author = {Abudoureyimu, Alimujiang and Aihaiti, Alimu and Abudoujilili, Nuliman and Tuergong, Mayila and Adili, Guzainuer and Maimaiti, Maihebubaimu and Mohetaer, Dilinuer and Maiamaitishawuti, Yimamumaimaiti},
title = {Diabetic Cardiomyopathy Uncovered: Transcriptomics, NLRP3, and Carvedilol Mechanisms},
journal = {Journal of Diabetes Research},
year = {2024},
doi = {10.1155/2024/9378405}
}
EUVIMED